$2.24
0.00% yesterday
Nasdaq, Sep 27, 09:02 pm CET
ISIN
US0053291078
Symbol
ADAG
Sector
Industry

Adagene Inc - ADR Stock price

$2.24
-0.77 25.64% 1M
-0.31 12.23% 6M
+0.31 15.88% YTD
+0.72 47.24% 1Y
-12.01 84.29% 3Y
-27.75 92.54% 5Y
-27.75 92.54% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
-0.00 0.08%
ISIN
US0053291078
Symbol
ADAG
Sector
Industry

Key metrics

Market capitalization $99.17m
Enterprise Value $24.29m
P/E (TTM) P/E ratio negative
EV/Sales (TTM) EV/Sales 29.27
P/S ratio (TTM) P/S ratio 119.48
P/B ratio (TTM) P/B ratio 1.75
Revenue growth (TTM) Revenue growth -96.36%
Revenue (TTM) Revenue $830.00k
EBIT (operating result TTM) EBIT $-37.46m
EPS (TTM) EPS $-0.73
P/E forward negative
P/S forward 16.53
EV/Sales forward 4.05
Short interest 0.04%
Show more

Is Adagene Inc - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Adagene Inc - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Adagene Inc - ADR forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a Adagene Inc - ADR forecast:

Buy
100%

Financial data from Adagene Inc - ADR

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Jun '24
+/-
%
0.83 0.83
96% 96%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 7.89 7.89
17% 17%
951%
- Research and Development Expense 30 30
47% 47%
3,664%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -37 -37
15% 15%
-4,514%
Net Profit -32 -32
11% 11%
-3,876%

In millions USD.

Don't miss a Thing! We will send you all news about Adagene Inc - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Adagene Inc - ADR Stock News

Neutral
GlobeNewsWire
12 days ago
- Confirmed partial responses (PRs) doubled to four since ASCO GI in MSS CRC patients without liver and peritoneal metastases for overall response rate (ORR) of 24% (4/17) with ADG126 10 mg/kg every three weeks (Q3W) in combination with pembrolizumab -
Neutral
GlobeNewsWire
3 months ago
SAN DIEGO and SUZHOU, China, July 12, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced a poster presentation at the upcoming ESMO Congress, taking place in Barcelona, Spain, 13-17 September 2024.
Neutral
GlobeNewsWire
4 months ago
SAN DIEGO and SUZHOU, China, May 22, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced its participation in multiple investor conferences in June 2024.
More Adagene Inc - ADR News

Company Profile

Adagene, Inc. engages in the discovery and development of novel antibody-based cancer immunotherapies. Its dynamic precision library platform is composed of the following proprietary technologies: NEObody, SAFEbody, and POWERbody. The company was founded by Ge Li and Pei Zhi Luo on February 25, 2011 and is headquartered in Suzhou, China.

Head office Cayman Islands
CEO Peizhi Luo
Employees 174
Founded 2011
Website www.adagene.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today